BJMO - volume 12, issue 5, september 2018
D. Schrijvers MD, PhD, L. van Asch , A. Van Goethem MD, E. Heylen MD, P. de Schouwer , S. van Eeckhout , V. Verheyen
Haematological and biochemical parameters are two of the important factors for safely administering oncological medication. These values should be available to the oncologist prior to administration of anticancer drugs in order to decide if they can be administered safely or if a dose reduction or postponement is necessary. In this project, the possibility of a blood sampling at home by a home care organisation 48–72 hours before the patient’s contact with the oncologist was evaluated to ensure that these parameters were available at the moment of consultation and to integrate these results in the patient electronic file.
From January 9, 2017, until April 30, 2017, 418 blood samplings were performed at home. Problems were not frequently encountered (4.7% of blood samplings). The pros and cons of this project are discussed. This project demonstrates that blood sampling at home is feasible and that the oncologist receives the required parameters in due time to ensure safe prescription and administration of anticancer medication.
(BELG J MED ONCOL 2018;12(5):247–251)
Read moreBJMO - volume 12, issue 2, march 2018
E. Verhelst MD, S. De Schepper MD, S. Declercq , D. Schrijvers MD, PhD
Primary leiomyosarcoma of the thyroid is a very rare tumour with an unfavourable prognosis. We present a sixty-year-old woman with a localised primary thyroid leiomyosarcoma. Despite a complete resection, a recurrence of the tumour was noticed six months later. After induction chemotherapy with ifosfamide and doxorubicin, the patient had renewed extensive surgery with removal of a tumour remnant and several lymph nodes. This was followed by radiotherapy. Eighteen months after diagnosis the patient is still alive and free of tumour on PET-CT. The case illustrates the high recurrence potential of a primary thyroid leiomyosarcoma despite a complete initial resection, but also the success of aggressive combined treatment.
(BELG J MED ONCOL 2018;12(2):75–78)
Read moreBJMO - volume 12, issue 3, february 2018
B. Sautois MD, PhD, J.C. Goeminne MD, S. Rottey MD, PhD, D. Schrijvers MD, PhD, F. Van Aelst MD, S. Van Bruwaene MD, PhD, S. Watkins , A. Simmons , Jowell Go , Melanie Collins , T. Golsorkhi , W. Abida MD, PhD, C. Ryan , Howard Scher , S. Chowdhury
BJMO - volume 12, issue 3, february 2018
B. De Laere PhD, Markus Mayrhofer , T. Whitington , P-J. Van Dam MD, P. Van Oyen , C. Ghysel , J. Ampe , P. Ost MD, PhD, Wim Demey MD, L. Hoekx MD, D. Schrijvers MD, PhD, B. Brouwers MD, PhD, W. Lybaert MD, E. Everaert MD, P. Van Kerckhove , D. De Maeseneer MD, M. Strijbos MD, PhD, A. Bols MD, PhD, K. Fransis , Nick Beije , Inge De Kruijff , S. Oeyen , A. Rutten MD, V. Van Dam , A. Brouwer , D. Goossens , Lien Heyrman , G. Van Den Eynden MD, PhD, J. Vandebroek , Jurgen Del-Favero , S. Sleijfer , A. Uhlen , Jeffrey Yachnin , S. Van Laere PhD, Henrik Grönberg , Johan Lindberg , L. Dirix MD
BJMO - volume 11, issue 3, may 2017
D. Schrijvers MD, PhD, T. Debacker MD
The characteristics of carcinogenesis are discussed in relation to prostate cancer. Some of these are already used as treatment targets in daily clinical practice, while in some, medications proved to be ineffective to interfere with these mechanisms of carcinogenesis.
Currently, treatments that have shown efficacy are addressing the mechanism of sustained proliferative activity, while there are some indications that immune modulation and agents interfering with DNA repair may play a role in the treatment of prostate cancer.
Other aspects of carcinogenesis need more study in patients with prostate cancer to show a benefit and they must be the scope of future research.
(BELG J MED ONCOL 2017;11(3):87–91)
Read moreBJMO - volume 11, issue 3, may 2017
D. Schrijvers MD, PhD, A. Van Goethem MD
In this practice guideline, the use of clinical indicators to increase the chance of completing six cycles of radium-223 in patients with metastatic castration-resistant prostate cancer is discussed.
(BELG J MED ONCOL 2017;11(3):107–109)
Read moreBJMO - 2017, issue 3, february 2017
B. De Laere PhD, P. Van Oyen , C. Ghysel , P. Ost MD, PhD, Wim Demey MD, L. Hoekx MD, D. Schrijvers MD, PhD, B. Brouwers MD, PhD, W. Lybaert MD, E. Everaert MD, J. Ampe , P. Van Kerckhove , D. De Maeseneer MD, M. Strijbos MD, PhD, A. Bols MD, PhD, K. Fransis , S. Oeyen , V. Van Dam , A. Brouwer , G. Van Den Eynden MD, PhD, A. Rutten MD, J. Vandebroek , S. Van Laere PhD, L. Dirix MD
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
